Perspective on the integration of radiomics and spatial omics in the analysis of the tumor microenvironment of bladder cancer and prospects for precision diagnosis and treatment

Category	Detail
Condition	Bladder Cancer
Key Mechanisms	Tumor immune microenvironment, spatial heterogeneity, immune checkpoint expression
Target Population	Patients with bladder cancer
Care Setting	Precision medicine and clinical practice

Bladder cancer has a heterogeneous tumor immune microenvironment affecting disease progression and treatment response.
Radiomics and spatial omics provide non-invasive assessment strategies for tumor characterization.
Immune checkpoint molecules like PD-1/PD-L1 are critical for predicting treatment response to immunotherapy.
Current therapies face challenges such as limited efficacy and drug resistance, especially in advanced cases.
Future directions include multimodal fusion and personalized therapeutic strategies driven by artificial intelligence.

Utilize high-throughput technologies for comprehensive analysis of the tumor immune microenvironment.

Consider the role of immune cell infiltration patterns and gene expression in treatment strategies.

Implement dynamic monitoring of the tumor microenvironment to optimize immunotherapy.

Be aware of the limitations of traditional tissue biopsies and imaging techniques in capturing tumor heterogeneity.

Patients diagnosed with non-muscle-invasive and muscle-invasive bladder cancer.

Immunotherapy response is linked to the immune microenvironment's composition and immune checkpoint expression.

Integrate radiomics and spatial omics for a comprehensive understanding of bladder cancer.
Focus on identifying reliable biomarkers through systematic analysis of immune cell dynamics.

Clinical Scorecard: Insights into Combining Radiomics and Spatial Omics for Evaluating the Bladder Cancer Tumor Microenvironment: Implications for Precision Diagnosis and Therapeutics